GeNeuro finds path forward for temelimab in non-active progressive MS

Two-year data from GeNeuro’s Phase IIb ANGEL-MS extension trial to treat relapsing-remitting multiple sclerosis has shown temelimab produced a sustained neuroprotective effect and provided an early signal for clinical benefit. The results support a move into non-active progressive MS patients, according to GeNeuro S.A. (Euronext:GNRO).

GeNeuro added €1.02 (28%) to €4.72 on Tuesday...